Vertex Pharmaceuticals has announced positive results from its ongoing Phase 1/2 study of VX-880, a stem cell-derived therapy for the treatment of type 1 diabetes. The results, presented at the American Diabetes Association's 84th Scientific Sessions in Orlando, reveal that the therapy can lead to insulin independence and decreased hypoglycemic events. Of the ten patients who completed their 180-day check-in, seven are no longer using insulin. Additionally, all 12 patients who received the full dose of VX-880 demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90, with three achieving insulin independence. Katherine Lewin reported on the findings at ADA2024.
#ADA2024 @VertexPharma revealed that all 12 patients who received the full dose of VX-880 #islets #stemcells as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 –3 pts achieved #insulin independence https://t.co/u2TzEUyXjR
New study presented at ADA Symposium in Orlando reveals promising results for stem cell-derived therapy in Phase 1/2 trial, showing T1D patients can achieve insulin independence with decreased hypoglycemic events.
Promising update from @VertexPharma's stem cell therapy for diabetes at #ADA2024. Katherine Lewin has the story for @endpts: "Ten patients completed their 180-day check in. Of those 10, seven are no longer using insulin" https://t.co/QqPFLA1kMW
Vertex reports positive results in stem cell trial for type 1 diabetes https://t.co/9HWPH15aeN via @cooney_liz for @statnews
So cool, and definitely something to watch. Vertex reports positive results in stem cell trial for type 1 diabetes. https://t.co/Ee2AIkhr5r
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions $VRTX https://t.co/P2ATMrvl5g